Reporting the Source of a Research Compound: The Materials Statement a Journal Expects

A materials statement for a purchased compound has one job: to let another laboratory obtain the same material and know what it was. In practice that means four facts — the supplier, the catalogue number, the lot or batch, and the purity together with the method that established it — plus the form the compound was supplied in and how it was stored. None of this is a stylistic preference. The ICMJE recommendations ask that methods be detailed enough for others with access to the data to reproduce the results ^[7], and the Key Resources Table used by Cell Press journals asks for each reagent's source — the company, manufacturer or individual that provided it — and an identifier such as a catalogue number, RRID or CAS number ^[1].

This article covers the statement itself: what goes in it, why the lot matters, how to report purity without overclaiming, and what to write when the paperwork is incomplete. How to structure the rest of a methods section, and how the Research Resource Identifier scheme works, are companion pieces in this cluster. The reader throughout is someone who bought a compound from a commercial research supplier and now has to describe it to an editor.

What journals and reporting frameworks actually ask for

The expectation is written down in several places, and the sources converge. Nature Portfolio journals require submissions to contain complete descriptions of the materials and reagents used, make availability of materials a condition of publication, and support the Resource Identification Initiative ^[2]. The MDAR framework — a cross-publisher minimum standard for life-science reporting — organises every material around three principles: accessibility, meaning whether and how it can be obtained; identification, meaning the information needed for unique and unambiguous designation and provenance; and characterisation, meaning the minimum description relevant for interpretation and replication ^[3]. For animal work, ARRIVE 2.0 asks that the procedures for each experimental group, including controls, be described in enough detail to allow others to replicate them ^[4].

Put those side by side and the statement for a synthetic compound takes an obvious shape. Accessibility is the supplier and catalogue number. Identification is the lot, plus a structural identifier for the compound itself. Characterisation is the purity, the method, and anything about the form of the solid — salt, counter-ion, water — that changes what a weighed amount actually contains ^[3].

The standard four, and what each one lets a reader do

The Key Resources Table formalises the first two. Its source column takes the provider; its identifier column takes the catalogue number written as "Cat#" followed by the number, with further identifiers separated by semicolons and "N/A" where none exists ^[1]. It does not ask for a lot number, and most journal instructions do not either. That is the gap worth closing anyway, for the reason in the next section.

Why the lot is the fact that matters most

A catalogue number identifies a product; a lot number identifies one run of it. For a synthetic peptide those can differ in ways that change an experiment: the purity achieved in that run, which impurities make up the remainder, the counter-ion left from purification, and the water content of the lyophilised solid. Two containers sold under the same catalogue number can hold measurably different amounts of the intended sequence per milligram weighed.

The literature on identifiability shows how often even the product level fails. Vasilevsky and colleagues assessed whether research resources — antibodies, cell lines, organisms, constructs and knockdown reagents — could be uniquely identified from the papers that used them, and found that 54% could not, regardless of field, journal impact factor or the journal's reporting requirements ^[5]. If more than half of resources cannot be pinned to a product, very few are being pinned to a batch.

For peptides, the lot-level variable most often overlooked is the salt form. Material purified by reversed-phase chromatography commonly carries trifluoroacetate unless it has been exchanged, and how much counter-ion a lyophilised peptide carries, and why it matters belongs to the lot, not the catalogue entry. Stating the salt form costs a few words and answers a question a careful reviewer will otherwise ask.

Reporting purity, and the method that established it

Purity is where materials statements most often overclaim. A figure such as 98% means little until the reader knows how it was measured, under what conditions and by whom. The Journal of Medicinal Chemistry's policy is a useful benchmark because it is explicit: tested compounds, whether synthesised or purchased, should be at least 95% pure; established methods such as HPLC or combustion analysis are acceptable; spectral data alone is not accepted as a criterion of purity; and where a compound falls below 95%, the actual figure is to be given ^[6]. Note the words "or purchased". Buying a compound does not move responsibility for its purity to the seller. The authors remain answerable for it.

• The figure, and whether it is a chromatographic area percentage or a content figure.
• The method and its detection conditions — for reversed-phase HPLC, at minimum the detection wavelength.
• Identity confirmation, usually by mass spectrometry, reported separately from purity.
• The source of the analysis: the supplier's certificate for that lot, an independent laboratory, or your own measurement ^[3].
• Anything known about content — net peptide content, counter-ion, water — or a plain statement that it was not determined.

The distinction in the first item is the one most often lost. An HPLC area percentage describes how much of the UV-absorbing material in a chromatogram sits in the main peak; it says nothing about the salt and water that make up part of every weighed milligram. A statement that reports 98% purity and then uses gross weight to calculate a concentration has quietly combined two different quantities. Where the compound is a peptide, identify it by sequence as well as by name — the conventions for writing a peptide sequence unambiguously are what let a reader confirm that the thing named is the thing that was made.

Handling material with incomplete provenance

Sometimes the record is incomplete: the lot was never written down, no certificate arrived, the supplier has since vanished, or the material came from a colleague's freezer. The MDAR pilot found that evaluators agreed least on exactly this kind of item — the provenance of cell lines, primary cultures and microbes — a reminder that provenance is hard to report even where registries exist ^[3]. The rules for a gap are short.

1. State what is known and stop there. "Obtained from [supplier], Cat# [number]; lot not recorded" is an honest sentence.
2. Never reconstruct a lot number from memory or from a later order. A plausible lot that was not the one used is worse than a blank.
3. Attribute every analytical figure. If the only purity figure is the supplier's, write "purity as stated by the supplier" ^[6].
4. If identity or purity bears on the conclusion and the documents cannot carry it, measure retained material and report that measurement with its method.
5. If nothing remains and no record exists, say so in the limitations rather than leaving a reviewer to find it.

Editors are generally more forgiving of a disclosed gap than a hidden one. The statement exists to let a reader weigh the evidence, and a sentence saying where the evidence is thin does exactly that.

A worked example statement

The statement below is built around a common reference peptide, with the supplier details left as placeholders. Every clause maps to one of the elements above, and it can be adapted line by line.

Angiotensin II (human; H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH; trifluoroacetate salt) was purchased from [Supplier] ([City, Country]; Cat# [number]; lot [string]). The supplier's certificate of analysis for this lot reported 98.1% purity by reversed-phase HPLC with UV detection at 214 nm and identity by electrospray mass spectrometry; net peptide content was not reported and was not independently determined. Material was received lyophilised, stored at −20 °C in the original sealed container, and dissolved in [solvent] on the day of each experiment. Concentrations are expressed on a gross-weight basis. The certificate is provided as Supplementary File [n].

• Name, species, full sequence and salt form: identification of the compound itself, independent of any supplier ^[3].
• Supplier, location, catalogue number and lot: accessibility and batch identity ^[1].
• Purity with method, detection conditions and source: characterisation, attributed to whoever performed it ^[6].
• An explicit note of what was not measured — here, net content.
• Storage and preparation: the handling another laboratory needs to repeat the work ^[4].
• The concentration basis, so a reader knows whether salt and water were corrected for.
• The certificate itself as a supplementary file, so the claim can be checked against the document ^[2].

The records that make the statement defensible

A materials statement is only as good as the file behind it, and that file is built at receipt, not at submission. Keep the lot string transcribed from the container, the certificate filed under both lot and report number, the dispatch paperwork, and a note of storage conditions from arrival onward — the part of the fuller record set a laboratory keeps for received material that a publication leans on. Nature Portfolio's requirement that materials be made available to readers, with any restriction stated in the paper, is far easier to meet when the lot and its paperwork were kept together from the start ^[2].

Write the statement while the material is still on the shelf. Everything in it is trivial to record on the day a parcel arrives and surprisingly hard to recover eighteen months later, when a reviewer asks which batch was used and whose number the purity figure is.